Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart test may predict bypass graft success

NCT ID NCT02527044

Knowledge-focused Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a pre-surgery test called FFR can predict how well arterial bypass grafts work six months after coronary artery bypass grafting (CABG). About 120 patients with multi-vessel heart disease will have an FFR test during their diagnostic angiogram. Six months after surgery, they get another angiogram to check graft function. The goal is to see if FFR values match graft health, which could guide future bypass decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fractional Flow Reserve (FFR) measurement
What this could lead to
If successful, this could help surgeons decide which arteries to bypass, potentially improving long-term graft function.
What could go wrong
This is an observational study, not a treatment trial. It only measures correlation, not outcomes. Results may not change practice directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2015

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. All patients with multi-vessel coronary artery disease undergoing elective or urgent first time coronary artery bypass grafting (CABG). 2. All patients undergoing diagnostic angiography and suspected to have multi-vessel disease for referral to CABG 3. Patients requiring both on-pump or off-pump CABG are accepted, as long as a arterial revascularisation is planned. 4. The patients must be over the age of 18. 5. CABG is the only procedure being conducted Exclusion Criteria: 1. Planned simultaneous surgical procedure unrelated to coronary revascularization (e.g. valve repair/replacement, aneurysmectomy, carotid endarterectomy or carotid stenting) 2. Redo CABG, or a percutaneous coronary intervention (PCI) within the last 6 months. 3. Severe renal insufficiency (preoperative creatinine \>150umol/L) contraindicating postoperative coronary angiography 4. Significant leukopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis 5. Women who are pregnant or are seeking to become pregnant 6. Must not have severe congestive heart failure (class III or IV New York Heart Association) at enrollment 7. Left ventricular ejection fraction less than 30% 8. Prior history of significant bleeding that might be expected to recur with CABG 9. Prisoners or institutionalized individuals 10. Geographic inaccessibility for the follow-up visits required by protocol 11. Concurrent enrollment in another clinical trial 12. Extra-cardiac illness that is expected to limit survival to less than 5 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder heart disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart disease

Contacts and locations

Locations

  • Clinique Saint-Luc Bouge

    Bouge, Belgium

  • University of Ottawa Heart Institute

    Ottawa, Ontario, K1Y4W7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.